No Data
apt medical inc. (688617.SH): It is expected that consumables related to atrial fibrillation will gradually increase in volume in the second half of 2025.
Gelonghui, November 12th | apt medical inc. (688617.SH) stated on the interactive platform that the company expects the consumption of atrial fibrillation-related supplies to gradually increase in the second half of 2025; the company's management holds a cautious and optimistic attitude towards the increase in atrial fibrillation supplies.
We Think That There Are Issues Underlying APT Medical's (SHSE:688617) Earnings
Third Quarter Report 2024
apt medical inc. (688617.SH): net income for the first three quarters was 0.528 billion yuan, a year-on-year increase of 30.97%.
Gelonghui reported on October 25th that apt medical inc. (688617.SH) released its third-quarter report, with revenue of 1.52 billion yuan in the first three quarters, a year-on-year increase of 25.63%, net income of 0.528 billion yuan, a year-on-year increase of 30.97%, non-GAAP net income of 0.508 billion yuan, a year-on-year increase of 41.08%, and basic earnings per share of 5.44 yuan.
Is APT Medical Inc.'s (SHSE:688617) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Apt Medical Inc. (688617.SH): Obtained medical instrument registration certificate for embolization spring coil.
Apt Medical Inc. (688617.SH) announced that its wholly-owned subsidiary, Hunan Apt Medical Instruments Co., Ltd., has obtained a medical instrument registration certificate for the product named Embolization Spring Coil. The acquisition of the aforementioned medical instrument registration certificate is conducive to enriching the company's product range, expanding its product layout in the peripheral field, continuously meeting diverse clinical demands, and further enhancing the company's core competitiveness.
If EPS Growth Is Important To You, APT Medical (SHSE:688617) Presents An OpportunityNo Data
No Data
